@article{ref1,
title="Synthetic cannabinoids and driving",
journal="Toxicologie analytique et clinique",
year="2015",
author="Mura, Patrick and Brunet, Bertrand",
volume="27",
number="1",
pages="41-44",
abstract="The recent apparition of synthetic cannabinoids (SC) on the drug market all over the world represents a new public health challenge because of their psychotropic effects, generally more or much more severe than that of marijuana. Their very important affinity for CB1 receptors may be responsible for cognitive and motor dysfunctions not compatible with safely operating a motor vehicle, as demonstrated by many published car crash cases. The few prevalence studies performed in blood samples from drivers suspected of impaired driving have shown that SC were present in 2 to 3% of cases. Up to now, no case-control study has been performed. So, the causal role for these compounds in road crashes has never been quantified. Such studies would be however necessary in order to provide important information on the relevance of implementing road side controls. Due to the continuously changing spectrum of currently available substances on the drug market, SC road side testing on drivers is a real analytical challenge. The French regulations related to car driving do not allow to test for SC and some changes would be necessary.  Keywords: Cannabis impaired driving <p /> <p>Language: fr</p>",
language="fr",
issn="2352-0078",
doi="10.1016/j.toxac.2015.01.001",
url="http://dx.doi.org/10.1016/j.toxac.2015.01.001"
}